Search

When considering adjuvant therapy preferences for younger patients ages 50 to 69 with early-stage, low genomic risk breast cancer, is it reasonable to omit radiotherapy or endocrine therapy after lumpectomy? A large retrospective cohort study at MSK found that locoregional recurrence rates were significantly lower for those who completed at least one form of adjuvant therapy after lumpectomy.

… Friday, October 10, 2025 When considering adjuvant therapy preferences for younger patients ages 50 to 69 with early-stage, low genomic risk breast cancer, is it reasonable to omit radiotherapy (RT) or endocrine therapy (ET) after lumpectomy? A large retrospective cohort study at MSK found that locoregional

Wider negative margins do not improve local control for ductal carcinoma in situ or invasive carcinoma when they are treated with lumpectomy and radiation therapy, our recent literature review shows.

… Monday, October 8, 2018 Wider negative margins do not improve local control for ductal carcinoma in situ or invasive carcinoma when they are treated with lumpectomy and radiation therapy, our recent literature review shows. However, ambiguity regarding margin width in such cases persists, leading to

Memorial Sloan Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer Research.

… Monday, January 6, 2014 Ludwig Center at Memorial Sloan Kettering Receives $90 Million in Funding For Cancer Research Memorial Sloan Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer

MSK experts discuss risk factors, symptoms, and treatment for male breast cancer.

… Monday, September 26, 2022 Breast cancer in men accounts for less than 1% of all cases of breast cancer . But because breast cancer is so common, that still amounts to about 2,700 cases in the United States every year. The current treatments for men with breast cancer are largely based on what doctors

Sequencing advanced endometrial tumors with the MSK-IMPACT™ assay provides an effective method for detecting microsatellite instability (MSI) and germline cancer predisposition syndromes

… Thursday, December 13, 2018 Sequencing advanced endometrial tumors with the MSK-IMPACT™ assay provides an effective method for detecting microsatellite instability (MSI) and germline cancer predisposition syndromes, which are collectively present in 16 percent of patients, as well as potentially actionable

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings were published today online in the British Medical Journal.

… Tuesday, September 14, 2010 A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online

Six students have successfully defended their dissertations and will receive their PhD degrees at Commencement on May 10.

… Monday, April 29, 2013 Six students at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences have successfully defended their dissertations. As part of Memorial Sloan Kettering’s 34th annual academic convocation on May 10, the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences

Dr. Nai-Kong V. Cheung, MD, PhD, the Enid A. Haupt Chair in Pediatric Oncology at MSK, was honored by the Advances in Neuroblastoma Research Association (ANRA) with its 2025 lifetime achievement award. An esteemed physician-scientist, Dr. Cheung leads a laboratory in Memorial Hospital Research Laboratories at MSK, which is focused on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

… Thursday, July 17, 2025 Dr. Nai-Kong V. Cheung, MD, PhD, the Enid A. Haupt Chair in Pediatric Oncology at MSK, was honored by the Advances in Neuroblastoma Research Association (ANRA) with its 2025 lifetime achievement award. An esteemed physician-scientist, Dr. Cheung leads a laboratory in Memorial

Computer models suggest breast cancer screening guidelines for people with mutations in the genes ATM, CHEK2, and PALB2.

… Thursday, February 17, 2022 Many people have heard of mutations in the BRCA1 and BRCA2 genes that are linked to an increased risk of certain cancers, including breast cancer . But there are other, less well-known genes in which hereditary mutations can also increase breast cancer risk, including ATM

MSK chemists are focusing on developing small-molecule drugs to target KRas, an important cancer protein.

… Wednesday, May 24, 2017 Summary MSK chemists are focusing on developing small-molecule drugs to target KRas, an important cancer protein. KRas is linked to nearly 30% of all cancers. Drug development is a complicated task. In the era of targeted therapies for cancer, medicinal chemists seek to design